BioSpace News Archive

Bruker Introduces Novel EVOQ™ DART-TQ + for Chromatography-Free Mass Spectrometry Aimed at the Applied Market Segments.

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy’s”), a global pharmaceutical company, announced that its tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase I study.

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data in support of its RaDaR assay for the detection of molecular residual disease (MRD) and recurrence in patients with high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Chimeric Therapeutics is please to announce that Jennifer Chow, Chief Executive Officer and Managing Director, will present at the Biotechnology Innovation Organization (BIO) International Convention, taking place June 5-8, 2023 at the Boston Convention and Exhibition Center in Boston.

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that new data will be presented on TG4001.

Alkeus Pharmaceuticals announced that it has raised a $150 million Series B financing to support the registration and launch of gildeuretinol, a potential disease-modifying, precision medicine for the treatment of Stargardt disease, a leading genetic cause of blindness in children and young adults.

Bicara Therapeutics will present positive interim data from its ongoing, open-label Phase 1/1b dose expansion study of BCA101, a first-in-class bifunctional EGFR/TGF-β antibody, at the 2023 American Society of Clinical Oncology Annual Meeting.

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced that the U.S. Food and Drug Administration has updated the Prescription Drug User Fee Act action date for the New Drug Application for nirogacestat for the treatment of adults with desmoid tumors.

The Department of Health – Abu Dhabi, the regulator of the healthcare sector in the Emirate, signed a Declaration of Collaboration with Eli Lilly, a global healthcare leader.

Endo International plc (OTC: ENDPQ) announced today that post-hoc data from two Phase 3 studies of XIAFLEX ® (collagenase clostridium histolyticum, or CCH, injection 0.9 mg) in treating men with Peyronie’s disease (PD) were published by peer-reviewed journal Urology ®.